BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)
Portfolio Pulse from
BioCardia, Inc. has completed enrollment and dosing for the low dose cohort in its CardiALLO Phase I/II trial, which uses BCDA-03 allogeneic mesenchymal stem cells to treat ischemic heart failure with reduced ejection fraction. The trial focuses on patients with elevated heart stress and inflammation markers, utilizing the FDA-approved Morph DNA steerable guide for therapeutic delivery.
February 13, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCardia has completed the low dose cohort enrollment for its CardiALLO Phase I/II trial, which could advance the development of BCDA-03 for treating ischemic heart failure. This milestone may positively influence investor sentiment.
The completion of the low dose cohort enrollment in the CardiALLO trial is a significant milestone for BioCardia, indicating progress in the development of BCDA-03. This could lead to positive investor sentiment as it shows advancement in their clinical pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100